Document is current
Any future updates will be listed below
-
Authors
Friedrich, Matthias
Pohin, Mathilde https://orcid.org/0000-0003-2809-9498
Jackson, Matthew A.
Korsunsky, Ilya https://orcid.org/0000-0003-4848-3948
Bullers, Samuel J.
Rue-Albrecht, Kevin https://orcid.org/0000-0003-3899-3872
Christoforidou, Zoe
Sathananthan, Dharshan
Thomas, Tom
Ravindran, Rahul
Tandon, Ruchi
Peres, Raphael Sanches
Sharpe, Hannah https://orcid.org/0000-0002-1194-2429
Wei, Kevin
Watts, Gerald F. M.
Mann, Elizabeth H. https://orcid.org/0000-0001-8339-2094
Geremia, Alessandra
Attar, Moustafa
,
,
Barone, Francesca
Brenner, Michael
Buckley, Christopher D.
Coles, Mark
Frei, Andreas P. https://orcid.org/0000-0002-9996-8251
Lassen, Kara G.
Powrie, Fiona M.
McCuaig, Sarah https://orcid.org/0000-0002-2304-7739
Thomas, Lloyd
Collantes, Elena
Uhlig, Holm H. https://orcid.org/0000-0002-6111-7355
Sansom, Stephen N. https://orcid.org/0000-0003-4569-8513
Easton, Alistair https://orcid.org/0000-0001-8148-5406
Raychaudhuri, Soumya https://orcid.org/0000-0002-1901-8265
Travis, Simon P. https://orcid.org/0000-0002-2690-4361
Powrie, Fiona M. https://orcid.org/0000-0003-3312-5929
- License Information
-
More Information
Article History
Received: 6 February 2021
Accepted: 26 August 2021
First Online: 21 October 2021
Competing interests
: F.M.P. received research support from Roche and Janssen, and consulting fees from GSK, Novartis and Genentech. H.H.U. received research support or consultancy fees from Janssen, Eli Lilly, UCB Pharma, BMS/Celgene, MiroBio, Mestag and OMass. S.P.T. received research support from AbbVie, Buhlmann, Celgene, IOIBD, Janssen, Lilly, Pfizer, Takeda, UCB, Vifor and the Norman Collisson Foundation; consulting fees from AbbVie, Allergan, Αbiomics, Amgen, Arena, Asahi, Astellas, Biocare, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Buhlmann, Celgene, Chemocentryx, Cosmo, Enterome, Ferring, Giuliani SpA, GSK, Genentech, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Merck, MSD, Neovacs, Novartis, NovoNordisk, NPS Pharmaceuticals, Pfizer, Proximagen, Receptos, Roche, Sensyne, Shire, Sigmoid Pharma, SynDermix, Takeda, Theravance, Tillotts, Topivert, UCB, VHsquared, Vifor and Zeria; and speaker fees from AbbVie, Amgen, Biogen, Ferring, Janssen, Pfizer, Shire, Takeda and UCB (no stocks or share options). M.A.J. is an employee of MiroBio Ltd. K.G.L. and A.P.F. are employees of Roche Ltd. All other authors declare no competing interests.
